Outcome of Board Meeting
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.4 pts more than Nifty Microcap 250 and 12.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis Limited's Board approved audited FY2026 consolidated results showing Total Income of Rs. 2,987.84 Crores (up 9.3% YoY) and Net Profit of Rs. 97.45 Crores (vs Rs. 3.24 Crores prior year). Standalone results showed a loss of Rs. 38.40 Crores due to inter-company eliminations and holding company expenses. Key decisions include: (1) Approval of ECB up to CHF 200 million (~Rs. 2,452 Crores) from promoter group company Aamanya AG at SARON+400bps to refinance existing debt; (2) Increase in borrowing limits from Rs. 1,700 Crores to Rs. 4,000 Crores subject to shareholder approval; (3) Re-appointment of T R Chadha & Co. LLP as statutory auditors for second term of 5 years. Auditors issued unmodified opinion with Emphasis of Matter on goodwill treatment (carrying value Rs. 580.96 Crores extended to 99-year life) and financial covenant deviation at standalone level (Rs. 84.44 Crores debentures) for which waivers are partially obtained.
The massive jump in consolidated PAT is partly base effect; standalone losses and covenant deviations indicate underlying stress at entity level. The large ECB from promoter at favorable rates will reduce interest costs but increases related-party exposure significantly. Shareholders should scrutinize the covenant deviation and standalone performance.